drugset / Trial / NCT01167751

Autologous Bone Marrow Derived Stem Cells for Acute Myocardial Infarction

NCT01167751 ↗

Phase 3 Completed 90 enrolled Royan Institute
RandomizedParallel-groupSingle-blindTreatment

Summary

One of the important reasons for human dying is Ischemic heart disease (IHD). The most reason is coronary artery disease. Beside morbidity, IHD induce myocardial infarction and necrosis which due to congestive heart failure. One therapeutic method is cellular cardiomyoplasty, which is to produce and substitute the cardiac cells with stem cell transplantation. Cell therapy is a potential therapeutic method to prevent ventricular remodeling after acute myocardial infarction. Human and animal studies have shown that stem cell trans plantation to myocardial infarcted zone can improve heart contractile function. The aim of this study is to comparison the effects of BM-derived AC133 and MNC implantation in patients with myocardial infarction.

Timeline

Start
2008-01
Primary completion
2012-06
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject AC133 Cell therapy — Other
Subject MNC Unknown — Other

Indications